Asymmetrical Flow Field Flow Fractionation (A4F) as part of the characterization techniques to be employed.

Focused on regulatory compliance.

Overview of NanoPilot Project.

NanoPilot will provide solutions for the preclinical and first clinical development steps.

Microfluidics will be intergrated in the plant.

A Pilot Plant for the Production of Polymer-based Nanopharmaceuticals in Compliance with GMP

NanoPilot has received funding from the European Union Framework Programme for Research and Innovation Horizon 2020. The objective of this four-year long project is to set-up a pilot plant operating under Good Manufacturing Practice (GMP) for the production of polymer-based nanopharmaceuticals. This pilot plant will accelerate the development of nanomedicine, currently in its infancy within the pharmaceutical sector.

Three different processes will be established for the production of three different nanopharmaceuticals.

State of the art production processes including micro reactors and highly advanced characterization techniques will ensure the quality of the nanodrugs.

Existing laboratories owned by the coordinator, will be adapted and certified within this project to enable the operability of the pilot plant.


During the project Nanopilot’s team will work to achieve different objectives:

  • Objectives based on industrial needs
  • Scientific objectives


NanoPilot will last 48 months. The work plan has been divided in 8 Work Packages including:

  • Research, Technology and Development (RTD)
  • Management (MGT)
  • Piloting (PIL)
  • Dissemination - Exploitation and Training activities (OTHER)


The NanoPilot consortium consists of 9 partners from 6 Member States:

  • 3 SMEs: iX-factory, Mejoran and Spinverse
  • 4 research groups: IK4-CIDETEC, National University of Ireland Galway, University of Santiago de Compostela and ADERA-UT2A
  • 2 industries: Sylentis and Chemtrix

Our Partners